Shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are on the rise following the announcement of a partnership with the University of Kentucky to conduct a Phase IIb clinical trial of SJ733, a drug candidate for vivax malaria treatment.
The study will evaluate the use of SJ733 in combination with tafenoquine for vivax malaria treatment, with the data informing the company’s New Drug Application (NDA) for the drug.
Dr. R. Kip Guy, the principal investigator, highlighted the potential impact of this study on malaria treatment, stating, “The upcoming study of SJ733 combined with tafenoquine has the potential to pave the way for very meaningful improvement in malaria treatment around the world.”
Implications for SXTP Stock
Following this news, SXTP stock has seen a significant increase in trading volume, with over 11.9 million shares traded compared to the daily average of 448,000 shares. The stock is up 28.9% as of Monday afternoon.
For more market news, investors can also check out updates on companies like Draganfly (NASDAQ:DPRO), KeyBank (NYSE:KEY), and Archer Aviation (NYSE:ACHR).
Analysis and Conclusion
The partnership between 60 Degrees Pharmaceuticals and the University of Kentucky for the Phase IIb clinical trial of SJ733 is a significant development in the field of malaria treatment. The potential for a new and improved treatment option for vivax malaria could have far-reaching implications for global health.
For investors, the positive news has resulted in a surge in SXTP stock price and trading volume. This demonstrates market confidence in the company’s potential for success in developing innovative treatments for infectious diseases.
Overall, this partnership highlights the importance of collaboration between pharmaceutical companies and research institutions in advancing healthcare solutions. Investors should keep an eye on further developments in this study and the potential impact on 60 Degrees Pharmaceuticals’ future growth and market position.
Source: Bukhta Yurii / Shutterstock.com